An underexplored relationship. Hypertension is a global public health problem affecting hundreds of millions of adults. While its links to cardiovascular disease are well-established, its relationship to cancer development has received growing but inconclusive attention. Prior studies on hypertension and urinary bladder cancer specifically have produced conflicting results, leaving the question unresolved.
Several biological pathways could connect hypertension to bladder cancer. Hypertension is a component of metabolic syndrome, which has independently been associated with cancer development. Hypertension may also block apoptosis, altering cell turnover regulation. Additionally, oxidative stress, which is a well-established driver of hypertension, is itself a recognized contributor to carcinogenesis.
The research question. This large nationwide population-based cohort study was designed to determine whether adults with essential hypertension face a higher risk of developing urinary bladder cancer than matched non-hypertensive adults, while rigorously controlling for known bladder cancer risk factors such as smoking, obesity, alcohol use, and metabolic comorbidities.
Taiwan's National Health Insurance Research Database. Data were drawn from the Longitudinal Health Insurance Dataset 2000, a systematically sampled subset of one million individuals from Taiwan's National Health Insurance Research Database, which covers over 23 million enrollees representing more than 99% of the entire Taiwanese population. The comprehensive coverage and validated record accuracy make this database a robust resource for population-based cancer research.
After applying strict exclusion criteria including removal of individuals with prevalent bladder cancer, age under 20, and survival time of zero, 639,842 individuals were available for analysis. Of these, 142,090 had diagnosed essential hypertension. Propensity score matching was performed one-to-one using a nearest-neighbor algorithm, matching on age, sex, index date, diabetes mellitus, chronic kidney disease, and gout to create two groups of 39,618 patients each with balanced baseline characteristics.
Rigorous outcome validation. Bladder cancer was defined conservatively, requiring either three or more outpatient diagnoses by a physician or urologist or at least one inpatient discharge diagnosis. Each case was then validated against bladder cancer-specific procedure codes including transurethral resection, cystoscopy, cystectomy, and intravesical instillation, ensuring that the outcome diagnosis reflected true clinical disease rather than administrative coding errors.
Follow-up continued for up to 13 years or until incident bladder cancer, death, or the end of 2013, with complete follow-up guaranteed by the universal insurance coverage preventing any dropout. Multivariable Cox proportional hazards models were adjusted for smoking-related diagnoses, morbid obesity, and chronic liver disease. Sensitivity analyses tested whether the risk association persisted across different follow-up time windows from year one through year seven and beyond.
More incident cancers in hypertensive patients. During 380,525 person-years of follow-up in the hypertension group and 372,020 in the comparison group, 248 and 186 patients developed bladder cancer respectively. This represented an adjusted hazard ratio of 1.32 with a 95% confidence interval of 1.09 to 1.60, indicating a statistically significant 32% increase in bladder cancer risk associated with hypertension.
Incidence rates per 10,000 person-years were 6.52 in hypertensive patients versus 5.00 in non-hypertensive patients for the total cohort. Men had higher absolute incidence rates than women (8.43 versus 4.81 per 10,000 person-years in the hypertension group), consistent with the well-known male predominance of bladder cancer regardless of hypertension status.
Sex-specific risk patterns. The elevated risk was statistically significant and clinically meaningful for women: hypertensive women had a 55% higher risk of bladder cancer than non-hypertensive women (adjusted hazard ratio 1.55, 95% CI 1.12 to 2.13). For men, the adjusted hazard ratio was 1.22 (95% CI 0.96 to 1.55), a similar direction of effect but not reaching statistical significance in the primary analysis. Sensitivity analyses showed significant elevation for men during specific follow-up windows including years one, three, four, five, and six.
Sustained elevation throughout 13 years. Sensitivity analyses systematically examined risk at each successive year of follow-up for the full cohort. The adjusted hazard ratio reached statistical significance as early as the first year at 1.43 and remained significantly elevated through all analyzed periods including year seven and beyond, where the risk remained approximately 46% higher in hypertensive patients (adjusted hazard ratio 1.46, 95% CI 1.09 to 1.97).
This temporal persistence argues against a simple detection bias explanation, where hypertensive patients might receive more medical encounters and therefore have bladder cancer diagnosed incidentally at higher rates. If detection bias were the primary driver, the risk elevation would be expected to diminish over time rather than persist throughout up to 13 years of follow-up.
Male-specific temporal risk windows. Among male patients specifically, the risk was statistically significant in the first, third, fourth, fifth, and sixth years of follow-up, with hazard ratios ranging from 1.33 to 1.53. The apparent attenuation beyond year six in male patients may reflect statistical power limitations as the at-risk population decreases over time rather than a true biological diminution of risk.
Independent association after thorough confounder control. Propensity score matching balanced the groups on major known bladder cancer risk factors including age, diabetes, chronic kidney disease, and gout. The Cox models then additionally adjusted for smoking-related diagnoses, morbid obesity, and chronic liver disease. The persistent association after this multi-level confounder control strengthens the case for an independent relationship between hypertension and bladder cancer.
Prior epidemiologic evidence was mixed. A European cohort of 578,700 individuals found a modest association in men but not women, while an Italian case-control study found a neutral relationship between drug-treated hypertension and urothelial carcinoma. The current study found a significant association in women but borderline significance in men, the opposite of the European finding, possibly reflecting differences in age distribution: 74.6% of women in the European cohorts were under 50, while the median age in the current study was 56 years.
Why women may be more affected. The reason hypertensive women in this cohort show a more pronounced and statistically significant risk elevation than men is not fully established. The authors note this as an important question for future research. One hypothesis is that sex-specific differences in oxidative stress pathways, hormonal influences on hypertension pathophysiology, or sex-stratified patterns of antihypertensive medication use could contribute to differential risk.
Strengths of the study design. The study benefits from a very large sample size with 79,236 propensity-matched individuals, up to 13 years of complete follow-up with no dropout, validated bladder cancer diagnoses via procedure codes, prospective data collection eliminating recall bias, and adjustment for multiple known confounders. The universal insurance coverage ensuring complete follow-up is a distinctive advantage over voluntary cohort studies.
Key limitations. The dataset lacked individual-level data on direct smoking history, diet, occupational chemical exposures, physical activity, and antihypertensive medication type. Smoking-related diagnoses such as chronic obstructive pulmonary disease were used as a proxy for smoking exposure, but this approach does not fully capture smoking dose. The possible residual confounding from unmeasured lifestyle and environmental factors cannot be excluded.
Clinical and research implications. The authors characterize the hazard ratio of 1.32 as modest in absolute clinical terms, meaning that hypertension alone should not trigger bladder cancer screening. However, the finding supports the need for mechanistic research into how hypertension or its downstream pathways involving oxidative stress and metabolic dysregulation may promote bladder carcinogenesis, and future studies should examine whether specific antihypertensive drug classes modify the risk.